易明医药发布股权激励计划，股价近期波动明显

Group 1 - The core point of the article is that Yiming Pharmaceutical (002826) has announced a draft for a restricted stock incentive plan for 2026, aimed at establishing an employee incentive mechanism, which may positively impact the company's long-term development [1][2]. Group 2 - On February 10, 2026, the company's board approved the draft of the restricted stock incentive plan, indicating a strategic move to enhance employee motivation and retention [2]. - The company's stock price experienced significant fluctuations over the past seven trading days, with a cumulative decline of approximately 4.38% from February 9 to 11, followed by a rebound of 2.51% on February 12, closing at 20.79 yuan [3]. - On February 12, there was a net inflow of approximately 6.6451 million yuan in main funds, accounting for 3.33% of the total trading volume, suggesting signs of short-term capital involvement [3]. - The company's stock performance was weaker compared to the pharmaceutical and biological sector and the overall market index during the same period [3].